Quince Therapeutics

Read the latest on Quince from Practical Neurology, which covers the recent publication of data from our Phase 3 ATTeST trial in The Lancet Neurology: https://lnkd.in/g6p8XHtD #biotech #raredisease #innovation        

Quince Investors: Read the latest profile story on Quince Therapeutics out today on Seeking Alpha: https://lnkd.in/eMy-Wz9m $QNCX #biotech #raredisease #innovation

Quince is pleased to announce the publication of data in The Lancet Neurology from our Phase 3 ATTeST clinical trial evaluating the safety and efficacy of our lead asset, EryDex (dexamethasone sodium phosphate encapsulated in autologous erythrocytes), for the treatment of A-T. Read more about the findings from largest completed study in A-T here: https://lnkd.in/gMUCzuUJ $QNCX #biotech #raredisease #innovation

Today, Quince provided a second quarter 2024 business update detailing our latest clinical, scientific, and corporate activities. Read more in the news release here: https://lnkd.in/gpZeCi8x #biotech #raredisease #innovation 

Quince Therapeutics is pleased to announce that the first patient has been dosed in the pivotal Phase 3 NEAT clinical trial of our lead asset EryDex for the treatment of Ataxia-Telangiectasia. Listen in here as Dirk Thye, our CEO & CMO, highlights this major clinical milestone for Quince, describes A-T and the high unmet medical need for this rare pediatric disease, and details our optimized NEAT study design being conducted under a Special Protocol Assessment agreement with the U.S. FDA. For more information on Quince Therapeutics, please contact ir@quincetx.com or visit www.quincetx.com. #biotech #raredisease #innovation 

Thank you Nasdaq for helping Quince celebrate the achievement of a major clinical milestone for our company today as we announced dosing the first patient in the pivotal Phase 3 NEAT clinical trial to evaluate our lead asset EryDex in patients with A-T. #raredisease #innovation 

Quince is pleased to announce that the first patient has been dosed in the pivotal Phase 3 NEAT clinical trial to evaluate the neurological effects of our lead asset EryDex in patients with Ataxia-Telangiectasia. Read more here: https://lnkd.in/gnnh_He2

Quince is pleased to announce that the U.S. FDA granted Fast Track designation for our EryDex System based on the potential of our lead asset EryDex to address a high unmet medical need for patients with A-T. Read more here: https://lnkd.in/e2tYTfdy

Today, Quince provided a business update detailing our latest clinical and corporate activities during the first quarter 2024. Read more in the news release here: https://lnkd.in/gVxKBRmC

Save the Date: Quince looks forward to presenting at The Citizen JMP Life Sciences Conference on May 13th beginning at 1:30 p.m. ET. More info here: https://lnkd.in/ggeUFneD